ClinicalTrials.gg
RecruitingNCT06742567POTAMIUpdated Dec 19, 2024

Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction

A Phase 3 interventional study of Apixaban 2.5 MG PO BID and Control (Standard treatment) in Acute Myocardial Infarction of Anterior Wall, Left Ventricular Thrombus and Prophylaxis, sponsored by National Institute of Cardiovascular Diseases, Pakistan. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by National Institute of Cardiovascular Diseases, Pakistan · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
472
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.

Read the detailed description

Objective To compare the safety and efficacy of Apixaban vs. placebo in the prevention of LV thrombus formation in patients with acute anterior myocardial and severe LV dysfunction following primary PCI in an open label, randomized controlled trial.

Methods:

Inclusion Criteria .Patients aged 18-65 years, presenting with acute anterior STEMI and severe LV dysfunction (EF\<35%) with antero-apical akinesis, dyskinesis, or aneurysm.

Exclusion Criteria

  • Patients with previous myocardial infarction or revascularization procedures.
  • Patients with cardiogenic shock
  • Patients with advanced CKD (Cr \< 2 and those on hemodialysis)
  • Recent ICH or major bleed requiring transfusion, low platelet counts\<100,000
  • History of CVA
  • Patients with atrial fibrillation or other indications for chronic anticoagulation
  • Pregnant patients and those with hematological disorders

Eligible patients will be enrolled after informed consent. Randomization will be undertaken once post PCI echocardiography is done and LV function is recorded. Patients randomized to the treatment arm will be given Apixaban 2.5 mg twice daily and DAPT for two weeks in addition to other guideline directed medical therapy (GDMT). After two weeks of triple therapy (DOAC+DAPT), aspirin will be dropped in the study arm. The control arm will be of standard care. After 4 weeks, treatment group will be switched to DAPT.

Follow up The primary endpoint will be the incidence of LV thrombus formation recorded at 4-week follow-up echocardiography. Patients' clinical status, side effects, and medication compliance will be recorded.

At 2-week: patients will be contacted via phone call to assess their clinical status, ensure drug compliance, discuss any necessary changes in drug regimen for those in the treatment group already prescribed on discharge, and inquire about any side effects.

At 4-week: patients will undergo an in-person follow-up where echocardiography will be conducted alongside a comprehensive assessment In case of any cardiac complaints, patients will be advised to visit the hospital or cardiologist promptly to complete a comprehensive clinical and laboratory workup. Primary endpoint

. Incidence of LV thrombus formation in the treatment arm vs. placebo at 4 week follow up echocardiography.

Secondary endpoints

  • composite of death, recurrent myocardial infarction, stent thrombosis, and heart failure hospitalization in experimental arm vs. control group.
  • Major and minor bleeding in experimental arm vs. control group
  • Discontinuation of the drug due to side effects in experimental arm vs. control group A clinical events committee whose members are unaware of study-group assignments will independently adjudicate all potential endpoints.
02

Conditions studied

  • Acute Myocardial Infarction of Anterior Wall
  • Left Ventricular Thrombus
  • Prophylaxis

Keywords

  • Acute myocardial infarction
  • severe left ventricular dysfunction
  • prevention of LV thrombus
  • DOAC
  • apixaban
03

In context

Anterior Wall Myocardial Infarction

36 studies on the registry are indexed under Anterior Wall Myocardial Infarction; 5 are open to participants now.

This study's planned enrollment of 472 is above the median of 110 across 28 interventional studies indexed under Anterior Wall Myocardial Infarction.

Browse Anterior Wall Myocardial Infarction studies →

Lead sponsor

National Institute of Cardiovascular Diseases, Pakistan is the lead sponsor of 23 studies on the registry; 13 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18-65 years
  • Presenting with acute anterior STEMI
  • Severe LV dysfunction (EF\<35%) with antero-apical akinesis, dyskinesis, or aneurysm
  • WIHTOUT evidence of LV thrombus.

Exclusion criteria

Exclusion Criteria:

  • Patients with previous anterior myocardial infarction or LAD revascularization procedures
  • Patients with cardiogenic shock
  • Patients with LV thrombus
  • Patients with advanced CKD (Cr > 2 and those on hemodialysis)
  • Recent ICH or major bleed requiring transfusion, low counts \<100,000
  • History of recent CVA ( within past three months)
  • Patients with atrial fibrillation or other indications for chronic anticoagulation
  • Pregnant patients and those with hematological disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
472 participants (estimated)

Study arms

  • Experimental
    Study arm (Apixaban 2.5 mg bid)

    Patients randomized to the treatment arm will be given Apixaban 2.5 mg twice daily and DAPT (aspirin (75 mg) + clopidogrel (75 mg)) for four weeks in addition to other guideline directed medical therapy (GDMT). After 4 weeks, treatment group will be switched to DAPT. o In the event of stent thrombosis during the study period, considering the high ischemic risk, the patient will be switched to ticagrelor instead of clopidogrel, and aspirin will be discontinued while Apixaban will be continued. After four weeks, the patient will be switched to DAPT (aspirin + ticagrelor).

    Drug: Apixaban 2.5 MG PO BID

  • Active comparator
    Control group

    The control arm will be of standard care i.e. DAPT in addition to other guideline directed medical therapy (GDMT).

    Drug: Control (Standard treatment)

Interventions

  • DrugApixabanStudies of ApixabanApixaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients randomized to the treatment arm will be given Apixaban 2.5 mg twice daily and DAPT (aspirin (75 mg) + clopidogrel (75 mg)) for four weeks in addition to other guideline directed medical therapy (GDMT). After 4 weeks, treatment group will be switched to DAPT.

  • DrugControl (Standard treatment)

    DAPT plus guideline directed medical therapy

06

What researchers measure

Primary outcomes

  1. Incidence of LV thrombus formation in the treatment arm vs. control group

    Incidence of LV thrombus formation in the treatment arm vs. control group at 4 week follow up echocardiography. This constitutes the primary endpoint of the trial

    Time frame: one month

Secondary outcomes

  1. Secondary Outcomes

    * composite of death, recurrent myocardial infarction, stent thrombosis, and heart failure hospitalization in the treatment arm vs. control group * Major and minor bleeding in the treatment arm vs. control group 3) Discontinuation of the drug due to side effects

    Time frame: one month

07

Study locations

1 of 1 sites recruiting
  • NICVD Pakistan
    Karachi, Sindh, Pakistan
    Recruiting
08

References and documents

Publications

  • Zhang Z, Si D, Zhang Q, Jin L, Zheng H, Qu M, Yu M, Jiang Z, Li D, Li S, Yang P, He Y, Zhang W. Prophylactic Rivaroxaban Therapy for Left Ventricular Thrombus After Anterior ST-Segment Elevation Myocardial Infarction. JACC Cardiovasc Interv. 2022 Apr 25;15(8):861-872. doi: 10.1016/j.jcin.2022.01.285. Epub 2022 Mar 30. PubMed 35367170 ↗
  • Camaj A, Fuster V, Giustino G, Bienstock SW, Sternheim D, Mehran R, Dangas GD, Kini A, Sharma SK, Halperin J, Dweck MR, Goldman ME. Left Ventricular Thrombus Following Acute Myocardial Infarction: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 Mar 15;79(10):1010-1022. doi: 10.1016/j.jacc.2022.01.011. PubMed 35272796 ↗
  • Bulluck H, Chan MHH, Paradies V, Yellon RL, Ho HH, Chan MY, Chin CWL, Tan JW, Hausenloy DJ. Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a meta-analysis. J Cardiovasc Magn Reson. 2018 Nov 8;20(1):72. doi: 10.1186/s12968-018-0494-3. PubMed 30404623 ↗

Individual participant data

Plan to share: Undecided — We plan on sharing IPD

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Nov 2025, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Dec 19, 2024
StartActual
Dec 2, 2024
Primary completionEst.
Nov 30, 2025
CompletionEst.
Nov 30, 2025
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06742567
Lead sponsor
National Institute of Cardiovascular Diseases, Pakistan
Responsible party
Professor Abdul Hakeem (professor, National Institute of Cardiovascular Diseases, Pakistan) — Principal investigator
First posted
Dec 19, 2024
Start date
Dec 2, 2024
Primary completion
Nov 30, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Dec 19, 2024

Study contacts

Abdul Hakeem, MD FACC FSCAI FASE
Contact
ahakeem@gmail.com
+92 3355554342
Sabha Bhatti, MD FASE FASNC FACC
Contact
drsabhabhatti@gmail.com
608-772-3048
Abdul Hakeem Professor of Cardiology, Director Cardiac Catheterization Labs, MD FACC FSCAI FASE
principal investigator · NICVD

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion